Physician profile
Sunil Mehra
NPI 1740252295
$388,096.96
in general payments reported to CMS, 2019-2025
40 companies · $53K in 2025
The $53K reported for 2025 was more than what 98% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49K · 2020: $43K · 2021: $93K · 2022: $36K · 2023: $34K · 2024: $82K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $151K · Food and Beverage: $14K · Travel and Lodging: $3,156 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $151,298.00 |
| Food and Beverage | $13,718.46 |
| Travel and Lodging | $3,155.96 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $224,236.89 | 2019-2025 | Breztri, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $140,762.08 | 2019-2023 | Shingrix, Arexvy |
| Sunovion Pharmaceuticals INC. | $10,502.05 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,879.20 | 2019-2025 | Ofev |
| Sanofi-Aventis U.S. LLC | $867.33 | 2024-2025 | |
| Amgen INC. | $676.08 | 2021-2024 | Tepezza, Tezspire |
| Abbott Laboratories | $609.49 | 2019-2025 | Freestyle Libre 3, Gallant |
| Viiv Healthcare Company | $600.00 | 2019 | |
| Insmed, INC. | $572.65 | 2019-2022 | |
| Intuity Medical INC | $555.39 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Boston Scientific Corporation | $466.49 | 2021-2025 | Avvigo Guidance System |
| Dexcom, INC. | $437.14 | 2022-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Janssen Pharmaceuticals, INC | $417.04 | 2019-2022 | |
| Novo Nordisk INC | $372.01 | 2021-2025 | Ozempic, Rybelsus |
| Horizon Therapeutics Plc | $367.34 | 2023 | Tepezza |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Mehra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.